

## General

# Treatment of cognitive deficits in schizophrenia using a new technique of Cognitive Training in Virtual Reality: a pilot study

Emanuele Bisso<sup>1</sup>, Pasquale Caponnetto<sup>2</sup>, Roberta Auditore<sup>3</sup>, Alfredo Pulvirenti<sup>1</sup>, Eugenio Aguglia<sup>1</sup>, Gabriele Avincola<sup>1</sup>, Abdalnaser Fakhrou<sup>4</sup>, Maria Salvina Signorelli<sup>1</sup>

<sup>1</sup> Department of Clinical and Experimental Medicine, University of Catania, 95125 Catania, Italy, <sup>2</sup> Department of Educational Sciences, Section of Psychology University of Catania, 95123 Catania, Italy, <sup>3</sup> Villa Chiara, psychiatric rehabilitation and research", 95030 Mascalucia (Catania), Italy, <sup>4</sup> Department of Psychological Sciences, (Doha), Qatar University

Keywords: Schizophrenia, Cognitive deficits, Virtual reality (VR), Cognitive training, Executive functioning.

<https://doi.org/10.52965/001c.129550>

---

## Health Psychology Research

Vol. 13, 2025

---

### Background

Cognitive impairments, prevalent in 75-80% of schizophrenia patients, severely impact rehabilitation and quality of life. Current therapies, including antipsychotics, have limited success in addressing these deficits. Virtual reality (VR) offers a promising avenue for cognitive training by providing realistic, interactive scenarios for skill application.

### Objective

This study evaluates the efficacy of a novel VR-based cognitive training intervention in improving cognitive deficits in schizophrenia compared to standard treatment as usual (TAU).

### Methods

A randomized clinical trial was conducted with 16 inpatients diagnosed with schizophrenia. Participants were allocated to either a VR intervention group, receiving six weekly sessions of VR cognitive training, or a control group undergoing TAU. Pre- and post-intervention assessments included the Trail Making Test, Positive and Negative Syndrome Scale, Frontal Assessment Battery, and Tower of London test. Two VR scenarios, "Supermarket" and "Beach," were developed to target working memory, attention, and executive functioning. Data were analyzed using t-tests and linear mixed-effects models.

### Results

The VR intervention group showed significant improvements in frontal lobe functioning as measured by the Frontal Assessment Battery (FAB) and trends toward better executive function and attention. Scenario-specific analyses revealed reduced errors, omissions, and execution times across sessions. However, broader cognitive and psychiatric symptom improvements were limited and did not persist after multiple-comparison corrections.

### Conclusion

VR cognitive training shows potential as an innovative tool for enhancing executive functioning in schizophrenia patients. While immediate task performance improved, broader cognitive impacts and psychiatric symptom reductions were minimal. Future research should focus on long-term efficacy, functional outcomes, and scalability of VR interventions.

## 1. INTRODUCTION

Cognitive impairment affects 75-80% of schizophrenia patients, significantly impacting rehabilitation, functioning, and quality of life.<sup>1</sup> These impairments pose a therapeutic challenge, as current antipsychotics have limited efficacy,

especially on negative symptoms, despite some improvements with second-generation antipsychotics.<sup>2-4</sup>

Virtual reality (VR) shows promise as a versatile therapy for schizophrenia, addressing delusions, hallucinations, cognitive, and social skills.<sup>5</sup> This novel intervention enhances cognitive performance like cognitive remediation

and allows users to apply these improved capabilities in a simulated, real-life context.<sup>6</sup>

Cognitive remediation, metacognitive training, social skills training, psychoeducation, family interventions are evidence-based treatments for cognitive stimulation,<sup>7</sup> but virtual reality is highly appealing, especially to young people, and enables realistic experiences with minimal ecological impact. We aimed to test a new VR-based therapy for cognitive symptoms, hypothesizing it would improve patients' cognitive domains more effectively than treatment as usual (TAU).

## 2. MATERIALS AND METHODS

### 2.1. PARTICIPANTS

Sixteen inpatients diagnosed with schizophrenia were recruited from May to October 2024 at the University Psychiatry Clinic "G. Rodolico" in Catania and the "Villa Chiara" Therapeutic Community in Mascalucia, Italy. Patients were selected through convenience sampling and randomly assigned using a computer-generated random number table to one of two groups: the VR intervention group or the control group. The VR intervention group participated in sessions designed to address attentional, mnemonic, and executive deficits, while the control group received treatment as usual (TAU), consisting of pharmacotherapy, psychoeducation, social skills training, and cognitive-behavioral therapy. Inclusion criteria required participants to have a DSM-5 diagnosis of schizophrenia, be clinically stable for at least three months, have no neurological or motor impairments affecting VR use, and be 18 years or older. Exclusion criteria included substance use disorders or an inability to provide informed consent.

### 2.2. OBJECTIVES

This study aims to evaluate the efficacy of a novel VR-based cognitive training intervention in improving cognitive deficits in schizophrenia patients. Specifically, the intervention targets working memory, attention, and executive functioning, and is compared to standard treatment as usual (TAU).

### 2.3. ASSESSMENT PROCEDURE

Both groups were assessed pre- and post-treatment with: Trial Making Test variants A, B, and B-A (TMT-A, TMT-B, TMT B-A),<sup>8</sup> Positive and Negative Syndrome Scale (PANSS),<sup>9</sup> Frontal Assessment Battery (FAB),<sup>10</sup> and Tower of London test (ToL),<sup>11</sup> to assess attention, executive skills, cognition, and psychotic symptoms.

### 2.4. INTERVENTION PROCEDURE

Intervention group received six VR-cognitive training sessions over 6 weeks, with one session weekly lasting about one hour, based on previous similar studies.<sup>12</sup> Each session involved two 3D interactive scenarios in non-immersive virtual reality, where patients executed specific tasks. In-

structions were given beforehand, and the rater (EB) did not interfere to avoid influencing results. A facilitator from the therapeutic community staff supported the patients with prompts and feedback as needed, in line with current evidence.<sup>13</sup>

## 2.5. VIRTUAL REALITY SCENARIOS

The intervention utilized a computer screen and controller to engage patients with the virtual environment, using NeuroVR v.2.0 software to create two interactive 3D scenarios:

Scenario 1 - "Supermarket" (fig 1): Aims to improve working memory, attention, and executive skills. Similarly to the store scenario designed by Keefe et al.<sup>14</sup> for VRFCAT, it simulates grocery shopping. It includes three tasks of increasing difficulty, each with memory and execution sub-tasks. The patient memorizes five objects, navigates a virtual supermarket to collect these items, and brings them to the cash desk. The number of items is based on normative data from the Rey Auditory Verbal Learning Test (RAVLT) for schizophrenia patients.<sup>15</sup> Each task ends when all required items are correctly collected and placed on the cash desk. Participants can retry tasks without limits until advancing. Each new level requires memorizing and collecting more items (two additional in the second and last tasks). Errors, omissions, and any help needed are recorded.

Scenario 2 - "Beach" (fig 2): Aims to improve working memory, attention, and executive skills, particularly the latter two. In the scenario replicating a large open space with a beach and a bathing establishment, patients undertake three tasks, identifying objects in the environment by their proximity, shape, or color to foster focused and sustained attention. They must recall the initial instructions from the experimenter e.g. "Collect only the object X that are in contiguity with the object Y", utilizing their working memory, and navigate the tasks strategically in this complex setting to demonstrate their executive skills. The number of exercises per session is flexible, allowing the patient to repeat tasks as needed to complete the session. The execution time, number of errors, aids used, and omissions are all tracked.

The selection of these scenarios was guided by a preliminary focus group with patients, discussing common daily activities to decide on the most engaging and useful scenarios.

## 2.6. STATISTICAL ANALYSIS

To test our hypotheses, we used a comprehensive statistical approach. Our primary hypothesis was that the VR intervention group would show greater cognitive improvements than the TAU-only group. We evaluated normal distribution with the Shapiro-Wilk test and expressed continuous variables as mean  $\pm$  standard deviation (SD) or median and interquartile range. Exploratory t-tests examined within-group changes and between-group differences, including paired t-tests for within-group comparisons and Welch's t-tests for between-group comparisons. We fitted a linear



Figure 1. Supermarket




Figure 2. Beach

mixed-effects model: Outcome ~ Arm \* Timepoint + (1|Participant), using F-tests to assess the significance of Arm, Timepoint, and their interaction. A p-adjusted value < 0.05 was considered statistically significant after FDR correction. Additional analyses for the intervention group included errors, omissions, aids, and execution time for tasks. Data were cumulated by session and analyzed descriptively. All analyses were performed using R version 4.1.0 with the lme4, lmerTest, and stats packages.

### 3. RESULTS

#### 3.1. CHARACTERISTICS OF THE SAMPLE

All participants were Caucasian, long-term facility patients, recruited either at the facility or during quarterly clinic visits. One individual in the intervention group had a comorbid social anxiety disorder. All participants remained clinically stable and continued their established psychopharmacological treatments. All patients' demographic data are reported in [Table 1](#).

Table 1. Characteristics of samples

|                       | Intervention group (N=8) | Control group (N=8) |
|-----------------------|--------------------------|---------------------|
| M/F                   | 5/3                      | 5/3                 |
| Mean age, males (SD)  | 37 years (7,21)          | 37 years (9,03)     |
| Mean age, female (SD) | 36 years (6,56)          | 33 years (7,21)     |
| Duration of illness   | 15 years (4,53)          | 14 years (3,87)     |
| Race - Caucasian      | 8                        | 8                   |
| Educational levels    |                          |                     |
| middle school diploma | 5                        | 4                   |
| high school diploma   | 2                        | 4                   |
| degree                | 1                        | 0                   |

**Table 2. Average results from scenario 1 and 2 by VR-session. (Note: execution time is expressed in second (s); SD: standard deviation)**

|            | Session        | 1        | 2        | 3        | 4        | 5        | 6       |
|------------|----------------|----------|----------|----------|----------|----------|---------|
| Scenario 1 | Execution time | 1220,125 | 1367,750 | 747,625  | 586,625  | 532,500  | 383,000 |
|            | SD             | 951,122  | 1075,765 | 558,168  | 521,293  | 410,190  | 279,691 |
|            | Error          | 1,500    | 1,500    | 0,875    | 0,500    | 0,375    | 0,000   |
|            | SD             | 2,138    | 1,773    | 1,246    | 0,756    | 0,744    | 0,000   |
|            | Omissions      | 2,250    | 2,750    | 1,375    | 0,875    | 0,500    | 0,375   |
|            | SD             | 1,389    | 1,753    | 1,598    | 1,126    | 0,756    | 0,518   |
|            | Aids           | 4,250    | 2,750    | 1,625    | 1,500    | 0,625    | 0,250   |
|            | SD             | 3,327    | 1,982    | 1,506    | 1,927    | 0,744    | 0,463   |
| Scenario 2 | Execution time | 1602,375 | 1654,000 | 1399,500 | 1086,000 | 1099,250 | 817,250 |
|            | SD             | 1227,557 | 1172,538 | 1159,183 | 836,048  | 960,044  | 613,036 |
|            | Error          | 1,625    | 0,875    | 0,750    | 0,125    | 0,375    | 0,125   |
|            | SD             | 1,408    | 1,126    | 2,121    | 0,354    | 1,061    | 0,354   |
|            | Omissions      | 0,250    | 0,125    | 0,375    | 0,000    | 0,000    | 0,000   |
|            | SD             | 0,707    | 0,354    | 0,518    | 0,000    | 0,000    | 0,000   |
|            | Aids           | 3,875    | 2,250    | 2,500    | 0,750    | 0,500    | 0,375   |
|            | SD             | 5,276    | 2,435    | 4,567    | 1,165    | 1,069    | 0,744   |

### 3.2. TRAINING RESULTS SCENARIO 1 (SUPERMARKET)

The training session for scenario 1 (supermarket) in [Table 3](#) shows a marked decrease in average execution time for the three tasks as sessions progressed, with reductions in errors, forgetfulness, and the need for aids indicating improvements in task completion and executive skills.

### 3.3 TRAINING RESULT SCENARIO 2 (BEACH)

For scenario 2 (beach), average completion times and errors also decreased over VR cognitive training sessions, as shown in [Table 2](#). Execution times improved, the need for aids dropped, and errors nearly vanished after the third session. Omissions remained minimal, with a slight peak in the third session due to the simpler memory requirement of tracking object counts.

### 3.4. ASSESSMENT RESULTS

Assessment tests were administered at baseline and study end, with data summarized in [Table 3](#). The VR cognitive training showed some improvements in executive skills and attention, although fewer effects remained significant after correction. The TMT-B revealed a significant main effect of Timepoint ( $F = 10.824$ ,  $p$ -adjusted = 0.0486), suggesting improvement over time in both groups. FAB demonstrated the most robust effects, with a significant main effect of Arm ( $F = 11.1622$ ,  $p$ -adjusted = 0.0486) and a highly significant interaction effect ( $F = 30.5569$ ,  $p$ -adjusted = 0.0027), providing strong evidence of greater improvement in the intervention group for frontal lobe functioning. This was further supported by a significant between-group difference at the post-intervention timepoint (T1) in the t-test results ( $t = -5.6392$ ,  $p$ -adjusted = 0.0050). Interestingly, after correc-

tion, the ToL test and TMT B-A scores no longer showed statistically significant effects, although trends towards improvement were observed. The PANSS subscales showed no significant effect.

## 4. DISCUSSION

This study demonstrates the potential of VR in treating schizophrenia spectrum disorders, consistent with similar studies.<sup>16,17</sup> After correction, VR cognitive training plus TAU significantly improved cognitive functions compared to TAU alone.

FAB scores showed significant improvements in frontal lobe functioning for the intervention group, and TMT-B scores indicated enhanced executive function and attention in both groups. Other cognitive measures like the ToL test and TMT A and B-A showed improvements but were not statistically significant. PANSS subscales showed no significant changes, meaning cognitive improvements did not reduce psychiatric symptoms. VR scenarios showed reduced execution times, errors, and need for assistance, particularly in simpler tasks. These findings suggest that VR cognitive training benefits frontal lobe functioning and executive function in schizophrenia. Future research should examine long-term effects, functional outcomes, quality of life, and broader cognitive and psychiatric impacts. Limitations include a small sample size, focus on specific cognitive domains, lack of long-term follow-up, and the absence of trial registration, which was not conducted due to the feasibility nature of the study.

**Table 3. Analysis of Cognitive and Psychiatric Measures: T-test Results and Linear Mixed-Effects Models**

| Scale            | Control T0      | T-test Results (t, p-adjusted)                    | Linear Mixed-Effects Model (F, p-adjusted)     |
|------------------|-----------------|---------------------------------------------------|------------------------------------------------|
| ToL - C - T0     | 10.51 (5.63)    | Between-group T0: t = 0.2202, p = 0.8905          | Arm: F = 0.0165, p = 0.9216                    |
| ToL - C - T1     | 11.68 (5.63)    | Between-group T1: t = 0.0184, p = 0.9856          | Timepoint: F = 1.5937, p = 0.7108              |
| ToL - I - T0     | 9.84 (6.42)     | Intervention T0 vs T1: t = -3.4213, p = 0.1000    | Arm:Timepoint: F = 0.0677, p = 0.9054          |
| ToL - I - T1     | 11.62 (6.58)    | Control T0 vs T1: t = -0.5140, p = 0.8259         |                                                |
| TMT-A - C - T0   | 65.88 (28.51)   | Between-group T0: t = -0.2051, p = 0.8905         | Arm: F = 0.0100, p = 0.9216                    |
| TMT-A - C - T1   | 62.12 (9.54)    | Between-group T1: t = 0.0295, p = 0.9856          | Timepoint: F = 1.2630, p = 0.7108              |
| TMT-A - I - T0   | 69.88 (47.21)   | Intervention T0 vs T1: t = 1.4218, p = 0.5485     | Arm:Timepoint: F = 0.1776, p = 0.9054          |
| TMT-A - I - T1   | 61.62 (46.94)   | Control T0 vs T1: t = 0.4184, p = 0.8259          |                                                |
| TMT-B - C - T0   | 153.00 (94.82)  | Between-group T0: t = -0.8978, p = 0.6356         | Arm: F = 1.2102, p = 0.7108                    |
| TMT-B - C - T1   | 89.00 (11.54)   | Between-group T1: t = -1.2652, p = 0.5807         | <b>Timepoint: F = 10.8240, p = 0.0486*</b>     |
| TMT-B - I - T0   | 217.00 (177.94) | Intervention T0 vs T1: t = 3.1980, p = 0.1088     | Arm:Timepoint: F = 0.0638, p = 0.9054          |
| TMT-B - I - T1   | 162.12 (163.06) | Control T0 vs T1: t = 2.0127, p = 0.4191          |                                                |
| TMT B-A - C - T0 | 87.12 (75.47)   | Between-group T0: t = -0.8767, p = 0.6356         | Arm: F = 1.7228, p = 0.7108                    |
| TMT B-A - C - T1 | 26.50 (8.42)    | Between-group T1: t = -1.7507, p = 0.4922         | Timepoint: F = 8.7189, p = 0.0709              |
| TMT B-A - I - T0 | 136.38 (139.83) | Intervention T0 vs T1: t = 1.9430, p = 0.4191     | Arm:Timepoint: F = 0.5735, p = 0.8745          |
| TMT B-A - I - T1 | 100.50 (119.26) | Control T0 vs T1: t = 2.2482, p = 0.3561          |                                                |
| FAB - C - T0     | 12.00 (2.20)    | Between-group T0: t = -1.5275, p = 0.5428         | <b>Arm: F = 11.1622, p = 0.0486*</b>           |
| FAB - C - T1     | 10.12 (1.36)    | <b>Between-group T1: t = -5.6392, p = 0.0050*</b> | Timepoint: F = 0.3772, p = 0.8745              |
| FAB - I - T0     | 14.00 (2.98)    | Intervention T0 vs T1: t = -3.5496, p = 0.1000    | <b>Arm:Timepoint: F = 30.5569, p = 0.0027*</b> |
| FAB - I - T1     | 15.50 (2.33)    | Control T0 vs T1: t = 4.2548, p = 0.0679          |                                                |
| PANSS-P - C - T0 | 18.12 (7.41)    | Between-group T0: t = 0.8255, p = 0.6356          | Arm: F = 1.4227, p = 0.7108                    |
| PANSS-P - C - T1 | 19.62 (8.30)    | Between-group T1: t = 1.3516, p = 0.5485          | Timepoint: F = 0.0634, p = 0.9054              |
| PANSS-P - I - T0 | 14.62 (9.43)    | Intervention T0 vs T1: t = 1.2556, p = 0.5807     | Arm:Timepoint: F = 0.3741, p = 0.8745          |
| PANSS-P - I - T1 | 14.00 (8.35)    | Control T0 vs T1: t = -0.4363, p = 0.8259         |                                                |
| PANSS-N - C - T0 | 20.75 (10.10)   | Between-group T0: t = 0.2530, p = 0.8905          | Arm: F = 0.2785, p = 0.9054                    |
| PANSS-N - C - T1 | 22.25 (10.54)   | Between-group T1: t = 0.6478, p = 0.7307          | Timepoint: F = 0.0378, p = 0.9166              |
| PANSS-N - I - T0 | 19.50 (9.67)    | Intervention T0 vs T1: t = 1.0000, p = 0.6311     | Arm:Timepoint: F = 0.1511, p = 0.9054          |
| PANSS-N - I - T1 | 19.00 (9.50)    | Control T0 vs T1: t = -0.2930, p = 0.8905         |                                                |
| PANSS-G - C - T0 | 44.38 (17.34)   | Between-group T0: t = 0.6633, p = 0.7307          | Arm: F = 1.2285, p = 0.7108                    |

| Scale            | Control T0    | T-test Results (t, p-adjusted)                | Linear Mixed-Effects Model (F, p-adjusted) |
|------------------|---------------|-----------------------------------------------|--------------------------------------------|
| PANSS-G - C - T1 | 50.25 (17.00) | Between-group T1: t = 1.4442, p = 0.5485      | Timepoint: F = 0.8234, p = 0.7882          |
| PANSS-G - I - T0 | 38.50 (18.08) | Intervention T0 vs T1: t = 1.2104, p = 0.5807 | Arm:Timepoint: F = 1.3759, p = 0.7108      |
| PANSS-G - I - T1 | 37.75 (17.61) | Control T0 vs T1: t = -1.0465, p = 0.6255     |                                            |
| PANSS-T - C - T0 | 83.25 (21.31) | Between-group T0: t = 0.8550, p = 0.6356      | Arm: F = 1.0818, p = 0.7108                |
| PANSS-T - C - t1 | 87.62 (34.75) | Between-group T1: t = 1.0999, p = 0.5807      | Timepoint: F = 0.0681, p = 0.9054          |
| PANSS-T - I - T0 | 71.75 (31.51) | Intervention T0 vs T1: t = 1.1657, p = 0.5807 | Arm:Timepoint: F = 0.4255, p = 0.8745      |
| PANSS-T - I - T1 | 69.88 (29.59) | Control T0 vs T1: t = -0.4632, p = 0.8259     |                                            |

ToL: Tower of London test; TMT A: Trail Making Test Part A; TMT B: Trail Making Test Part B; TMT B A: Difference between Trail Making Test Part B and A; FAB: Frontal Assessment Battery; PANSS P: Positive and Negative Syndrome Scale - Positive symptoms; PANSS N: Positive and Negative Syndrome Scale - Negative symptoms; PANSS G: Positive and Negative Syndrome Scale - General psychopathology; PANSS T: Positive and Negative Syndrome Scale - Total score. T0: Baseline; T1: Post-intervention; \* Statistically significant (p < 0.05) after Benjamini-Hochberg correction for multiple comparisons.

## 5. CONCLUSIONS

This study suggests that VR cognitive training may benefit individuals with schizophrenia, particularly in enhancing executive functioning. While task performance improved, effects on most cognitive measures and psychiatric symptoms were limited. The intervention's potential lies in its scalability and adaptability. Further research is needed to fully understand its efficacy and potential for improving functional outcomes.

.....

### AUTHOR CONTRIBUTIONS

E.B. conceived and developed the original idea, supported by M.S.S.. E.B and A.F. administered the VR treatment, collected data and assessments, and wrote the original manuscript and P.C. collaborated in data collection and assess-

ment, and with M.S.S., in the recruitment of subjects too. A.P. performed the statistical analysis. M.S.S., P.C. and A.F. revised the paper. M.S.S., P.C., E.A., A.F. G.A., R.A. supervised the project and provided organizational support and critical feedback. All Authors have read and approved the final version of the manuscript.

### FUNDING

This research received no external funding.

### CONFLICTS OF INTEREST

The authors declare no conflict of interest.

Submitted: January 07, 2025 EDT. Accepted: January 25, 2025 EDT. Published: March 23, 2025 EDT.

## REFERENCES

1. Reichenberg A. The assessment of neuropsychological functioning in schizophrenia. *Dialogues in clinical neuroscience*. 2022;12(3):383-392. doi:[10.31887/DCNS.2010.12.3/areichenberg](https://doi.org/10.31887/DCNS.2010.12.3/areichenberg)
2. Davidson M, Galderisi S, Weiser M, et al. Cognitive Effects of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: A Randomized, Open-Label Clinical Trial (EUFEST). *American journal of psychiatry*. 2009;166(6):675-682. doi:[10.1176/appi.ajp.2008.08060806](https://doi.org/10.1176/appi.ajp.2008.08060806)
3. Mortimer AM, Joyce E, Balasubramaniam K, Choudhary PC, Saleem PT. Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia. *Human Psychopharmacology: Clinical and Experimental*. 2007;22(7):445-454. doi:[10.1002/hup.865](https://doi.org/10.1002/hup.865)
4. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. *The International Journal of Neuropsychopharmacology*. 2005;8(3):457-472. doi:[10.1017/s146114570500516x](https://doi.org/10.1017/s146114570500516x)
5. Bisso E, Signorelli MS, Milazzo M, et al. Immersive Virtual Reality Applications in Schizophrenia Spectrum Therapy: A Systematic Review. *International Journal of Environmental Research and Public Health*. 2020;17(17). doi:[10.3390/ijerph17176111](https://doi.org/10.3390/ijerph17176111)
6. Schroeder AH, Bogie BJM, Rahman TT, Thérond A, Matheson H, Guimond S. Feasibility and Efficacy of Virtual Reality Interventions to Improve Psychosocial Functioning in Psychosis: Systematic Review. *JMIR Mental Health*. 2022;9(2). doi:[10.2196/28502](https://doi.org/10.2196/28502)
7. Barlati S, Nibbio G, Vita A. Evidence-based psychosocial interventions in schizophrenia: a critical review. *Current Opinion in Psychiatry*. 2024;37(3):131-139. doi:[10.1097/ycp.0000000000000925](https://doi.org/10.1097/ycp.0000000000000925)
8. Reitan RM. Validity of the Trail Making Test as an Indicator of Organic Brain Damage. *Perceptual and Motor Skills*. 2016;8(3):271-276. doi:[10.2466/pms.1958.8.3.271](https://doi.org/10.2466/pms.1958.8.3.271)
9. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. *Schizophrenia Bulletin*. 1987;13(2):261-276. doi:[10.1093/schbul/13.2.261](https://doi.org/10.1093/schbul/13.2.261)
10. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB. *Neurology*. 2000;55(11):1621-1626. doi:[10.1212/wnl.55.11.1621](https://doi.org/10.1212/wnl.55.11.1621)
11. Shallice T. Specific impairments of planning. *Philosophical Transactions of the Royal Society of London B, Biological Sciences*. 1997;298(1089):199-209. doi:[10.1098/rstb.1982.0082](https://doi.org/10.1098/rstb.1982.0082)
12. Freeman D, Yu LM, Kabir T, et al. Automated virtual reality (VR) cognitive therapy for patients with psychosis: study protocol for a single-blind parallel group randomised controlled trial (gameChange). *BMJ Open*. 2019;9(8). doi:[10.1136/bmjopen-2019-031606](https://doi.org/10.1136/bmjopen-2019-031606)
13. Schlosser DA, Fisher M, Gard D, Fulford D, Loewy RL, Vinogradov S. Motivational deficits in individuals at-risk for psychosis and across the course of schizophrenia. *Schizophrenia Research*. 2014;158(1-3):52-57. doi:[10.1016/j.schres.2014.06.024](https://doi.org/10.1016/j.schres.2014.06.024)
14. Keefe RSE, Davis VG, Atkins AS, et al. Validation of a Computerized test of Functional Capacity. *Schizophrenia Research*. 2016;175(1-3):90-96. doi:[10.1016/j.schres.2016.03.038](https://doi.org/10.1016/j.schres.2016.03.038)
15. Badcock JC, Dragovic M, Dawson L, Jones R. Normative Data for Rey's Auditory Verbal Learning Test in Individuals with Schizophrenia. *Archives of Clinical Neuropsychology*. 2011;26(3):205-213. doi:[10.1093/arclin/acr005](https://doi.org/10.1093/arclin/acr005)
16. Miranda B, Rego PA, Romero L, Moreira PM. Application of Immersive VR Serious Games in the Treatment of Schizophrenia Negative Symptoms. *Computers*. 2024;13(2). doi:[10.3390/computers13020042](https://doi.org/10.3390/computers13020042)
17. Shen ZH, Liu MH, Wu Y, Lin QQ, Wang YG. Virtual-reality-based social cognition and interaction training for patients with schizophrenia: A preliminary efficacy study. *Frontiers in Psychiatry*. 2022;13. doi:[10.3389/fpsy.2022.1022278](https://doi.org/10.3389/fpsy.2022.1022278)